» Articles » PMID: 35160190

Pathophysiology of Heart Failure: A Role for Peripheral Blood Mononuclear Cells Mitochondrial Dysfunction?

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Feb 15
PMID 35160190
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) is a leading cause of hospitalization in patients aged more than 65 years and is associated with high mortality rates. A better comprehension of its physiopathology is still needed, and, in addition to neurohormonal systems and sodium glucose co-transporter 2 modulations, recent studies focus on the mitochondrial respiration of peripheral blood circulating cells (PBMCs). Thus, cardiovascular metabolic risk factors and cellular switch with an increased neutrophil/lymphocytes ratio might favor the decreased PBMC mitochondrial respiration observed in relation with HF severity. PBMCs are implicated in the immune system function and mitochondrial dysfunction of PBMC, potentially induced by their passage through a damaged heart and by circulating mitoDAMPs, which can lead to a vicious circle, thus sustaining negative cardiac remodeling during HF. This new approach of HF complex pathophysiology appears to be a promising field of research, and further studies on acute and chronic HF with reduced or preserved LVEF are warranted to better understand whether circulating PBMC mitochondrial function and mitoDAMPs follow-ups in HF patients might show diagnosis, prognosis or therapeutic usefulness.

Citing Articles

Acute Severe Hypoxia Decreases Mitochondrial Chain Complex II Respiration in Human Peripheral Blood Mononuclear Cells.

Riou M, Charles A, Enache I, Evrard C, Pistea C, Giannini M Int J Mol Sci. 2025; 26(2).

PMID: 39859418 PMC: 11765662. DOI: 10.3390/ijms26020705.


Hallmarks of cancer in patients with heart failure: data from BIOSTAT-CHF.

van den Berg P, Yousif L, Markousis-Mavrogenis G, Shi C, Bracun V, Tromp J Cardiooncology. 2024; 10(1):47.

PMID: 39103886 PMC: 11299300. DOI: 10.1186/s40959-024-00246-w.


Transcriptional profiles associated with coronary artery disease in type 2 diabetes mellitus.

Nevado Jr J, C Cutiongco-de la Paz E, Paz-Pacheco E, Jasul Jr G, Aman A, Deguit C Front Endocrinol (Lausanne). 2024; 15:1323168.

PMID: 38706700 PMC: 11066158. DOI: 10.3389/fendo.2024.1323168.


Beyond acute infection: molecular mechanisms underpinning cardiovascular complications in long COVID.

Mostafa R, Moustafa A Front Cardiovasc Med. 2024; 11:1268571.

PMID: 38495940 PMC: 10942004. DOI: 10.3389/fcvm.2024.1268571.


Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disorders-Is There a Breakthrough?.

Grujic-Milanovic J, Rajkovic J, Milanovic S, Jacevic V, Miloradovic Z, Nezic L Antioxidants (Basel). 2023; 12(12).

PMID: 38136208 PMC: 10740850. DOI: 10.3390/antiox12122088.


References
1.
Dai D, Rabinovitch P, Ungvari Z . Mitochondria and cardiovascular aging. Circ Res. 2012; 110(8):1109-24. PMC: 3867977. DOI: 10.1161/CIRCRESAHA.111.246140. View

2.
Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T . Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124(2):499-508. PMC: 3904627. DOI: 10.1172/JCI72227. View

3.
Maayah Z, Takahara S, Dyck J . The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin. Arch Toxicol. 2020; 95(1):1-9. DOI: 10.1007/s00204-020-02876-2. View

4.
Lopaschuk G, Verma S . Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020; 5(6):632-644. PMC: 7315190. DOI: 10.1016/j.jacbts.2020.02.004. View

5.
Fontes J, Rose N, cihakova D . The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine. 2015; 74(1):62-8. PMC: 4677779. DOI: 10.1016/j.cyto.2014.12.024. View